Amgen (NQ:AMGN)

The biotech needs to overcome an issue most drugmakers face at some point.

Should You Buy the Dip on This Top Growth Stock? ↗

October 05, 2024

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗

October 03, 2024

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill ↗

Topics Stocks

October 02, 2024

Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge...

Via Benzinga

Topics Lawsuit

(AMGN) - Analyzing Amgen's Short Interest ↗

September 30, 2024

Via Benzinga

Analyst Expectations For Amgen's Future ↗

September 25, 2024

Via Benzinga

Market Whales and Their Recent Bets on AMGN Options ↗

September 24, 2024

Via Benzinga

AskSlim Market Week - Friday, Sep. 27 ↗

September 27, 2024

An analysis and commentary on the financial markets.

Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review ↗

September 27, 2024

The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades' ↗

Topics Stocks

September 26, 2024

Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.

Via Benzinga

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs ↗

September 25, 2024

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...

Via Benzinga

What the Options Market Tells Us About Amgen ↗

September 23, 2024

Via Benzinga

Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN) ↗

September 20, 2024

NASDAQ:AMGN Shows Potential for a Breakout.

Via Chartmill

Where Will Amgen Be in 5 Years? ↗

September 20, 2024

There are plenty of ongoing positive developments with the biotech giant.

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗

September 25, 2024

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗

September 24, 2024

Regeneron filed an appeal after a court's decision, which was issued under seal.

Via Benzinga

2 Weight-Loss Stocks That Could Rocket Higher This Year ↗

September 24, 2024

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.

The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling ↗

September 23, 2024

Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.

Topics Stocks

Behind the Scenes of Amgen's Latest Options Trends ↗

September 19, 2024

Via Benzinga

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗

September 23, 2024

These two stocks could be rivals in the intense GLP-1 space in the future.

Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy? ↗

September 23, 2024

Are Verizon, Amazon, Cisco, Amgen, and the S&P Biotech Bull 3X Shares ETF poised to make your portfolio skyrocket? In this video, I take a closer look.

Can These 5 Assets Skyrocket Your Portfolio? ↗

September 22, 2024

Being able to recite the potential problems in the world does not make you a good investor.

Topics ETFs Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 18, 2024

Via Benzinga

The Bull Market Strengthened, Let The Naysayers Say Nay... ↗

September 15, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Growth-oriented businesses can make excellent additions to a well-diversified portfolio.

Topics ETFs

2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500 ↗

September 13, 2024

Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now ↗

September 12, 2024

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.